drugset
drugset / Trial / NCT05881993

Study of CBP-4888 in Healthy, Non-Pregnant Female Subjects

NCT05881993 ↗

Phase 0 Completed 45 enrolled Comanche Biopharma
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a Phase I, first-in-human, single-center, randomized, double-blind, placebo-controlled, single ascending dose study to evaluate the safety, tolerability, and PK of ascending doses of CBP-4888.

Timeline

Start
2023-05-22
Primary completion
2024-05-22
Completion
2024-05-22

Drugs

EvaluationDrugModalityDoseRoute
Subject CBP-4888 Unknown — Subcutaneous

Indications

No indication recorded.